Neurodegeneration and neuroprotection in multiple sclerosis

Current Pharmaceutical Design

Volumn 18, Issue 29, 2012, Pages 4471-4474

  Stangel, Martin ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Axonal injury; Clinical trial; Neurodegeneration; Neuroprotection; Remyelination; Repair

Indexed keywords

AXONIN 1; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM CHANNEL; CILIARY NEUROTROPHIC FACTOR; EPHRIN B3; ERYTHROPOIETIN; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; LAMOTRIGINE; MINOCYCLINE; MYELIN ASSOCIATED GLYCOPROTEIN; N ACETYLASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NOGO A ANTIBODY; POTASSIUM CHANNEL; RECOMBINANT SOMATOMEDIN C; RILUZOLE; SODIUM CHANNEL; SOMATOMEDIN C;

ADD ON THERAPY; ARTICLE; AXONAL INJURY; CENTRAL NERVOUS SYSTEM; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOMODULATION; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMYELINIZATION; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

ANIMALS; AXONS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS;

EID: 84866431318     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802502189     Document Type: Article

References (57)

1. Kornek B, Lassmann H Axonal pathology in multiple sclerosis. A historical note. Brain Pathol 1999; 9: 651-656.
2. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393-399.
3. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338: 278-285.
4. De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001; 58: 65-70.
5. De Stefano N, Matthews PM, Liqun F, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998; 121: 1469-1477.
6. Piaton G, Gould RM, Lubetzki C. Axon-oligodendrocyte interactions during developmental myelination, demyelination and repair. J Neurochem 2010; 114: 1243-12460.
7. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010; 133: 1900-1913.
8. Confavreux C, Vukusic S. Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129: 606-616.
9. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004; 63: 1779-1787.
10. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999; 46: 296-304.
11. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253: 98-108.
12. Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci 2008; 31: 247-269.
13. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Brück W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125: 2202-2212.
14. Medana I, Martinic MA, Wekerle H, Neumann H. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am J Pathol 2001; 159: 809-815.
15. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurology 2002; 1: 232-241.
16. Srinivasan R, Sailasuta N, Hurd R, Nelson S, Pelletier D. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 2005; 128: 1016-1025.
17. Pitt D, Werner P, Raine CS. Glutamate excitotoxicity in a model of multiple sclerosis. Nat Med 2000; 6: 67-70.
18. Craner MJ, Newcombe J, Black JA, Hartle C, Cuzner ML, Waxman SG. Molecular changes in neurons in multiple sclerosis: altered axonal expression of Nav1.2 and Nav1.6 sodium channels and Na+/Ca2+ exchanger. Proc Natl Acad Sci U SA 2004; 101: 8168-8173.
19. Young EA, Fowler CD, Kidd GJ, et al. Imaging correlates of decreased axonal Na+/K+ ATPase in chronic multiple sclerosis lesions. Ann Neurol 2008; 63: 428-435.
20. Trapp BD, Stys PK. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol 2009; 8: 280-291.
21. Stys PK. General mechanisms of axonal damage and its prevention. J Neurol Sci 2005; 233: 3-13.
22. Dutta R, McDonough J, Yin X, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006; 59: 478-489.
23. Mahad DJ, Ziabreva I, Campbell G, et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009; 132: 1161-1174.
24. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128: 2705-2712.
25. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 2000; 123 (Pt 9): 1845-1849.
26. Frischer JM, Bramow S, Dal Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132: 1175-1189.
27. Derfuss T, Parikh K, Velhin S, et al. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A 2009; 106: 8302-8307.
28. Mathey EK, Derfuss T, Storch MK, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007; 204: 2363-2372.
29. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
30. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786-1801.
31. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9: 438-446.
32. Black JA, Liu S, Hains BC, Saab CY, Waxman SG. Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE. Brain 2006; 129: 3196-3208.
33. Black JA, Liu S, Carrithers M, Carrithers LM, Waxman SG. Exacerbation of experimental autoimmune encephalomyelitis after withdrawl of phenytoin and carbamazepin. Ann Neurol 2007; 62: 21-33.
34. Friese MA, Craner MJ, Etzensperger R, et al. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med 2007; 13: 1483-1489.
35. Stadelmann C, Kerschensteiner M, Misgeld T, et al. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 2002; 125: 75-85.
36. Petratos S, Azari MF, Ozturk E, Papadopoulos R, Bernard CC. Novel therapeutic targets for axonal degeneration in multiple sclerosis. J Neuropathol Exp Neurol 2010; 69: 323-334.
37. Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 2007; 13: 1228-1233.
38. Mi S, Miller RH, Tang W, et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol 2009; 65: 304-315.
39. Irvine KA, Blakemore WF. Remyelination protects axons from demyelination-associated axon degeneration. Brain 2008; 131: 1464-1477.
40. Stangel M, Hartung H-P. Remyelinating strategies for the treatment of multiple sclerosis. Prog Neurobiol 2002; 68: 361-376.
41. Stangel M. Remyelinating and neuroprotective treatments in multiple sclerosis. Expert Opin Investig Drugs 2004; 13: 331-347.
42. Franklin RJ, ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008; 9: 839-855.
43. Zivadinov R. Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology 2007; 68(Suppl 3): S72-S82.
44. Filippi M, Agosta F. Imaging biomarkers in multiple sclerosis. J Magn Reson Imaging 2010; 31: 770-788.
45. Kapoor R, Furby J, Hayton T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 2010; 9: 681-688.
46. Kalkers NF, Barkhof F, Bergers E, van Schijndel R, Polman CH. The effect of the neuroprotective agent riluzole on MRI papameters in patients with progressive multiple sclerosis: a pilot study. Mult Scler 2002; 8: 532-533.
47. Ehrenreich H, Fischer B, Norra C, et al. Exploring human recombinant erythropoietin in chronic progressive multiple sclerosis. Brain 2007; 130: 2577-2588.
48. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 1999; 96: 13496-13500.
49. Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 2002; 51: 215-223.
50. Skripuletz T, Miller E, Moharregh-Khiabani D, et al. Beneficial effects of minocycline on cuprizone induced cortical demyelination. Neurochem Res 2010; 35: 1422-1433.
51. Metz LM, Li D, Traboulsee A, et al., Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebocontrolled trial. Mult Scler 2009; 15: 1183-1194.
52. Frank JA, Richert N, Lewis B, et al. A pilot study of recombinant insulin-like growth factor-1 in seven multiple sclerosis patients. Mult Scler 2002; 8: 24-29.
53. Stangel M, Boegner F, Klatt CH, Hofmeister C, Seyfert S. A placebo- controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68: 89-92.
54. Noseworthy JH, O'Brien PC, Petterson TM, et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001; 56: 1514-1522.
55. Noseworthy JH, O'Brien PC, Weinshenker BG, et al. IV immunoglobulin does not reverse established weakness in MS. A doubleblind, placebo-controlled trial. Neurology 2000; 55: 1135-1143.
56. Wahlgren NG, Ahmed N. Neuroprotection in cerebral ischemia: facts and fancies - the need for new approaches. Cerebrovasc Dis 2004; 17(Suppl 1): 153-166.
57. de Lecinana MA, Diez-Tejedor E, Gutierrez M, Guerrero S, Carceller F, Roda JM. New goals in ischemic stroke therapy: the experimental approach - harmonizing science with practice. Cerebrovasc Dis 2005; 20(Suppl 2): 159-168.